<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800016</url>
  </required_header>
  <id_info>
    <org_study_id>ILI875-P002</org_study_id>
    <nct_id>NCT04800016</nct_id>
  </id_info>
  <brief_title>Real-World Study of Vivity Intraocular Lenses (IOLs)</brief_title>
  <official_title>Real-World Study of AcrySofâ„¢ IQ Vivity Extended Vision Intraocular Lenses (IOLs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical study is to assess the clinical performance of the&#xD;
      AcrySof IQ Vivity Extended Vision IOL in a Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical study, subjects will be implanted with the AcrySof IQ Vivity Extended Vision&#xD;
      IOL in both eyes. The second eye surgery will occur 7-28 days after the first eye. A total of&#xD;
      11 scheduled visits are planned, including a screening visit, two operative visits, and 8&#xD;
      postoperative visits. The total expected duration of the subject's participation will be&#xD;
      about 13 months. This study will be conducted in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Monocular Distance Corrected Intermediate Visual Acuity (DCIVA) - First Eye</measure>
    <time_frame>Month 6 post second eye implantation</time_frame>
    <description>Intermediate visual acuity will be assessed at 66 centimeters (cm) with best correction of distance visual acuity in place. This endpoint is pre-specified for the first implanted eye.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Monocular Distance Corrected Near Visual Acuity (DCNVA) - First Eye</measure>
    <time_frame>Month 6 post second eye implantation</time_frame>
    <description>Near visual acuity will be assessed at 40 centimeters (cm) with best correction of distance visual acuity in place. This endpoint is pre-specified for the first implanted eye.&#xD;
.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ocular adverse events</measure>
    <time_frame>Up to Month 12 post second eye implantation</time_frame>
    <description>Ocular adverse events will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of secondary surgical interventions (SSIs)</measure>
    <time_frame>Up to Month 12 post second eye implantation</time_frame>
    <description>Secondary surgical interventions will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of severe or most bothersome visual disturbances (subjects surveyed with QUVID questionnaire)</measure>
    <time_frame>Up to Month 12 post second eye implantation</time_frame>
    <description>Subjects will be surveyed using the QUVID questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes Achieving 0.2 logMAR or better Best Corrected Distance Visual Acuity (BCDVA) - First Eye</measure>
    <time_frame>Month 6 post second eye implantation</time_frame>
    <description>Distance visual acuity will be assessed at 4 meters (m) with best correction of distance visual acuity in place. This endpoint is pre-specified for the first implanted eye.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Aphakia</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Vivity IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AcrySof IQ Vivity Extended Vision IOL implanted in the capsular bag in the posterior chamber of the eye during cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcrySof IQ Vivity Extended Vision IOL</intervention_name>
    <description>UV and blue-light filtering extended depth of focus foldable IOL intended to provide a full range of vision from distance to functional near.</description>
    <arm_group_label>Vivity IOL</arm_group_label>
    <other_name>Model DFT015</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ Vivity Extended Vision IOL</description>
    <arm_group_label>Vivity IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand and sign an approved informed consent;&#xD;
&#xD;
          -  Willing and able to attend all scheduled study visits as required per protocol;&#xD;
&#xD;
          -  Diagnosed with cataracts in both eyes;&#xD;
&#xD;
          -  Pre-operative regular corneal astigmatism less than 1.0 diopter (D);&#xD;
&#xD;
          -  Planned bilateral cataract removal by phacoemulsification.&#xD;
&#xD;
          -  Other protocol-specified inclusion criteria may apply.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Glaucoma, diabetic retinopathy, retinitis pigmentosa and any pathologic changes&#xD;
             associated with the optic nerve;&#xD;
&#xD;
          -  Clinically significant corneal diseases;&#xD;
&#xD;
          -  Clinically significant/severe dry eye that would affect study measurements based on&#xD;
             the investigator's expert medical opinion;&#xD;
&#xD;
          -  Previous intraocular surgery history;&#xD;
&#xD;
          -  Pregnancy or lactation during study or planning to be pregnant/lactating;&#xD;
&#xD;
          -  Systemic medications that, in the opinion of the Investigator, may confound the&#xD;
             outcome or increase the risk to the subject;&#xD;
&#xD;
          -  Other planned ocular surgical procedures;&#xD;
&#xD;
          -  Patients who can only undergo cataract surgery in one eye.&#xD;
&#xD;
          -  Other protocol-specified exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Lead, Surgical</last_name>
    <role>Study Director</role>
    <affiliation>Alcon (China) Ophthalmic Product Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alcon Call Center</last_name>
    <phone>1-888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hainan Bo'ao Super Hospital Co., Ltd.</name>
      <address>
        <city>Qionghai</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Intraocular lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

